For example, CTLA-4 inhibitors like ipilimumab can prompt a T-cell attack on the uveal melanocytes, leading to uveitis, especially in melanoma patients (melanoma antigens cross-react with ocular melanocytes in Vogt-Koyanagi-Harada syndrome–like fashion) (50). Here, CTLA4 is linked to uveitis.